[Analysis on the Quality Status of in Vitro Diagnostic Reagents for National Medical Device Supervision and Inspection in 2020].
Lists
Only you see this
Abstract
It is suggested that manufacturers of <i>in vitro</i> diagnostic reagents should improve the binding force of the quality management system, strengthen the awareness of risk management, attach importance to communicate with regulatory authorities, study standards sufficiently and strengthen the management of instructions. It is also suggested that the regulatory authorities should strengthen supervision and inspection, and further complete the evaluation guidance and standard publicity and implementation.
BibTeX
@inproceedings{li2022analysis,
author = {Xiao Li and Xintao Zhang and Qing Hao and Jiong Zhu and Wei Hong},
title = {{[Analysis on the Quality Status of in Vitro Diagnostic Reagents for National Medical Device Supervision and Inspection in 2020].}},
booktitle = {PubMed},
year = {2022},
doi = {10.3969/j.issn.1671-7104.2022.04.022},
}Loading related content...